Use of population pharmacokinetic modeling to characterize intramuscular pharmacokinetics for ziprasidone in schizophrenic patients

M. U. Shad, S. H. Preskorn, J. Miceli, K. Wilner

    Research output: Contribution to journalArticle

    1 Scopus citations

    Abstract

    Objective: To characterize the pharmacokinetics (PK) of the rapid-acting intramuscular (IM) formulation of the novel antipsychotic ziprasidone in schizophrenic patients. Methods: Building upon a population PK model established from data-rich, single-dose studies performed in healthy subjects, the multiple-dose disposition of ziprasidone was characterized in patients receiving ziprasidone IM dose of 5mg (n=6), 10mg (n=6), and 20 mg (n=6) administered four times daily for three days. PK sampling was limited to 12 samples on Day 1 and 14 on Day 3. Results: The results were consistent with predictions from single dose, showing attainment of peak exposure within approx 30 min, dose related increases in exposure, and little drug accumulation. Conclusions: The approach used here demonstrated that population PK modeling is a useful tool in understanding drug disposition where PK sampling is limited. Ziprasidone IM has a predictable, linear PK profile. Therapeutic plasma levels are attained rapidly.

    Original languageEnglish (US)
    Number of pages1
    JournalClinical pharmacology and therapeutics
    Volume65
    Issue number2
    DOIs
    StatePublished - Jan 1 1999

    ASJC Scopus subject areas

    • Pharmacology
    • Pharmacology (medical)

    Fingerprint Dive into the research topics of 'Use of population pharmacokinetic modeling to characterize intramuscular pharmacokinetics for ziprasidone in schizophrenic patients'. Together they form a unique fingerprint.

  • Cite this